Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:47 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Gabapentin on Postoperative Pain Associated With Ureteroscopy and Stents Insertion
NCT03151746 · Northwestern University · PHASE4 · terminated · last registry update 2022-07-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Insufficient enrollment” | – | Registry record, Northwestern University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CACNA1H within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-06-27Phase 3 first posted: Tanta University, Baclofen 10mg + Gabapentin (NCT05921604)
- 2023-04-27Results posted on the registry: Medical College of Wisconsin, Methadone + Morphine (NCT02558010)
- 2023-04-24Phase 3 first posted: Yale University, Naltrexone Pill + Naltrexone Injection (NCT05827159)
- 2023-04-21Results posted on the registry: The University of Texas Health Science Center, Houston, Ketamine plus usual care + Usual Care (NCT04129086)
- 2023-04-13Also stopped (withdrawn): M.D. Anderson Cancer Center, Gabapentin (NCT05100160)
- 2023-01-26Also stopped (withdrawn): Massachusetts General Hospital, Gabapentin + Placebo (NCT02957097)
- 2022-12-21Phase 3 first posted: Jocelyn Fitzgerald, Multimodal Bundle Drugs + Bladder Instillation (NCT05658874)
- 2022-12-06Results posted on the registry: Campbell Clinic, a drug against CACNA1H (NCT04294680)
- 2022-11-17Phase 3 first posted: Tanta University, Ondansetron 8mg + Gabapentin (NCT05620641)
- 2022-11-17Also stopped (withdrawn): Vinmec Healthcare System, a drug against CACNA1H (NCT04133142)
- 2022-11-10Results posted on the registry: Boston Medical Center, Low-dose naltrexone + Gabapentin (NCT04052139)
- 2022-11-08Results posted on the registry: Inova Health Care Services, Oral Gabapentin and Intravenous Acetaminophen (IV APAP) + Opiate based pain regimen. (NCT03679013)
- 2022-10-06Results posted on the registry: New York State Psychiatric Institute, Gabapentin (NCT03205423)
- 2022-09-21Also stopped (withdrawn): Johns Hopkins University, a drug against CACNA1H (NCT04421196)
- 2022-09-14Phase 3 first posted: Research Institute of Ophthalmology, Egypt, Pregabalin 150mg gabapentin 400mg (NCT05539924)
- 2022-09-06Also stopped (withdrawn): Wake Forest University Health Sciences, Tramadol + Gabapentin (NCT04939987)
- 2022-07-28Results posted on the registry: University of Arkansas, Gabapentin + Buprenorphine (NCT02543944)
- 2022-07-12Also stopped (terminated): University of Alberta, Ropinirole + Gabapentin (NCT03708237)
- 2022-07-11Results posted on the registry: NYU Langone Health, Pre-op Multimodal analgesia (MMA) regimen + standard post-op oxycodone (NCT04522206)
- 2022-07-06Also stopped (withdrawn): University of Massachusetts, Worcester, Bupivacaine Liposome Injection (NCT04134442)
- 2022-06-27Also stopped (withdrawn): Assistance Publique Hopitaux De Marseille, Perampanel + conventional antiepileptic treatment (NCT03636958)
- 2022-06-22Phase 3 first posted: Zagazig University, Propranolol , gabapentin (NCT05427474)
- 2022-05-05Also stopped (terminated): Stanford University, Gabapentin + Lorazepam (active control) (NCT01067144)
- 2022-05-03Results posted on the registry: New York State Psychiatric Institute, Gabapentin + Placebo (NCT02557945)
- 2022-05-03Also stopped (terminated): New York State Psychiatric Institute, Gabapentin + Placebo (NCT02557945)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision